D. E. Shaw & Co., Inc. Mirati Therapeutics, Inc. Call Options Transaction History

D. E. Shaw & Co., Inc.

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $3.79 Million - $7.55 Million	-50,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $4.8 Million - $6.69 Million	-30,200 Reduced 37.66%	50,000 $8.57 Million
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $3.24 Million - $4.81 Million	20,000 Added 33.22%	80,200 $17.6 Million
Q3 2020 Nov 16, 2020	BUY	$113.26 - $167.27 $1.13 Million - $1.67 Million	10,000 Added 19.92%	60,200 $10 Million
Q2 2020 Aug 14, 2020	BUY	$72.01 - $120.39 $720,100 - $1.2 Million	10,000 Added 24.88%	50,200 $5.73 Million
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $697,800 - $1.16 Million	10,000 Added 33.11%	40,200 $3.09 Million
Q4 2019 Feb 14, 2020	BUY	$70.76 - $128.86 $1.42 Million - $2.58 Million	20,000 Added 196.08%	30,200 $3.89 Million
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $2.71 Million - $3.81 Million	-34,800 Reduced 77.33%	10,200 $795,000
Q4 2018 Feb 14, 2019	BUY	$32.0 - $47.43 $1.44 Million - $2.13 Million	45,000 New	45,000 $1.91 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.